

Antonio Bossi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1868803/publications.pdf>

Version: 2024-02-01

21
papers

1,644
citations

1040056

9
h-index

940533

16
g-index

21
all docs

21
docs citations

21
times ranked

2014
citing authors

#	ARTICLE	IF	CITATIONS
1	Glomerular resistances predict long-term GFR decline in type 2 diabetic patients without overt nephropathy: a longitudinal subgroup analysis of the DEMAND trial. <i>Acta Diabetologica</i> , 2022, 59, 309-317.	2.5	2
2	Patient-Support Program in Diabetes Care During the Covid-19 Pandemic: An Italian Multicentric Experience. <i>Patient Preference and Adherence</i> , 2022, Volume 16, 113-122.	1.8	4
3	Survival of Colorectal Cancer Patients With Diabetes Mellitus: A Meta-Analysis. <i>Canadian Journal of Diabetes</i> , 2021, 45, 186-197.e2.	0.8	22
4	Preventing microalbuminuria with benazepril, valsartan, and benazepril+valsartan combination therapy in diabetic patients with high-normal albuminuria: A prospective, randomized, open-label, blinded endpoint (PROBE) study. <i>PLoS Medicine</i> , 2021, 18, e1003691.	8.4	7
5	Pasta Consumption and Connected Dietary Habits: Associations with Glucose Control, Adiposity Measures, and Cardiovascular Risk Factors in People with Type 2 Diabetes—TOSCA.IT Study. <i>Nutrients</i> , 2020, 12, 101.	4.1	17
6	A Response To: Sodium-Glucose Cotransporter 2 Inhibitors and Major COVID-19 Outcomes: Promising Mechanisms, Conflicting Data, and Intriguing Clinical Decisions. <i>Diabetes Therapy</i> , 2020, 11, 3007-3009.	2.5	3
7	PERSistent Sitagliptin treatment & Outcomes (PERS&O 2.0) study, long-term results: a real-world observation on DPP4-inhibitor effectiveness. <i>BMJ Open Diabetes Research and Care</i> , 2020, 8, e001507.	2.8	0
8	ANDREW: A Multicenter, Prospective, Observational Study in Patients with Type 2 Diabetes on Persistent Treatment with Dulaglutide. <i>Diabetes Therapy</i> , 2020, 11, 2677-2690.	2.5	2
9	Lack of Efficacy of SGLT2-i in Severe Pneumonia Related to Novel Coronavirus (nCoV) Infection: No Little Help from Our Friends. <i>Diabetes Therapy</i> , 2020, 11, 1605-1606.	2.5	16
10	Insulin Management for Type 1 Diabetic Patients During Social Alcohol Consumption: The SPRITZ Study. <i>Current Diabetes Reviews</i> , 2020, 16, 619-627.	1.3	0
11	Effects of valsartan, benazepril and their combination in overt nephropathy of type 2 diabetes: A prospective, randomized, controlled trial. <i>Diabetes, Obesity and Metabolism</i> , 2019, 21, 1177-1190.	4.4	14
12	SaO006INCREASED PRE-GLOMERULAR RESISTANCE AND KIDNEY HYPOPERFUSION MAY SUSTAIN ACCELERATED GFR DECLINE IN HYPERTENSIVE, TYPE 2 DIABETICS WITH NORMAL AND HIGH NORMAL ALBUMINURIA. <i>Nephrology Dialysis Transplantation</i> , 2018, 33, i317-i317.	0.7	2
13	Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial. <i>Lancet Diabetes and Endocrinology</i> , 2017, 5, 887-897.	11.4	231
14	Skin Oil Staining to Avoid Infusion Set Cannula Crimping. <i>Journal of Diabetes Science and Technology</i> , 2016, 10, 1201-1202.	2.2	0
15	Comment on Muraki et al. Potato Consumption and Risk of Type 2 Diabetes: Results From Three Prospective Cohort Studies. <i>Diabetes Care</i> 2016;39:376-384. <i>Diabetes Care</i> , 2016, 39, e151-e151.	8.6	0
16	PERS&O (PERSistent Sitagliptin treatment & Outcomes): observational retrospective study on cardiovascular risk evolution in patients with type 2 diabetes on persistent sitagliptin treatment. <i>BMJ Open Diabetes Research and Care</i> , 2016, 4, e000216.	2.8	3
17	GLP-1 response to 2 energy-matched snacks. <i>American Journal of Clinical Nutrition</i> , 2014, 100, 1398.	4.7	0
18	Glomerular Hyperfiltration and Renal Disease Progression in Type 2 Diabetes. <i>Diabetes Care</i> , 2012, 35, 2061-2068.	8.6	259

#	ARTICLE	IF	CITATIONS
19	Effects of Manidipine and Delapril in Hypertensive Patients With Type 2 Diabetes Mellitus. Hypertension, 2011, 58, 776-783.	2.7	86
20	Preventing Microalbuminuria in Type 2 Diabetes. New England Journal of Medicine, 2004, 351, 1941-1951.	27.0	952
21	Side-effects, structure, and H2-receptor antagonists. Lancet, The, 1992, 339, 1366.	13.7	24